3 Defence Optics Maker, CNG and Piped Gas Distributor and Generic Drugs Maker Stocks With a Strong Future Roadmap: Paras Defence and Space Technologies, Indraprastha Gas and Alembic Pharmaceuticals
- November 5, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Paras Defence and Space Technologies, Indraprastha Gas and Alembic Pharmaceuticals: ROE of 11.9% to 13.5% and FY22 to FY26 revenue CAGR of 8.4% to 27.6%. Prices as of 4 Nov 2026.
Quick Answer
The three defence optics, gas and generic drug stocks to watch are Paras Defence and Space Technologies, Indraprastha Gas and Alembic Pharmaceuticals. Their return on equity ranges from 11.9% to 13.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 27.6%. Indraprastha Gas has the highest return on equity at 13.5%, while Paras Defence and Space Technologies has the fastest revenue growth at 27.6% a year. Prices are based on the 4 November 2026 close, and this article is educational, not investment advice.
Defence optics, gas and generic drug stocks bring together companies with a visible plan for the years ahead. Paras Defence and Space Technologies, Indraprastha Gas and Alembic Pharmaceuticals cover a defence optics and electronics maker, a CNG and piped gas distributor and a generic drugs maker.
This list covers three defence optics, gas and generic drug stocks with complete current figures: Paras Defence and Space Technologies, Indraprastha Gas and Alembic Pharmaceuticals. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Defence Optics, Gas and Generic Drug Stocks?
Defence optics, gas and generic drug stocks are listed companies that make optics and defence electronics, distribute compressed natural gas to vehicles and piped gas to homes, and sell generic formulations in India and abroad. Their earnings depend on defence orders, gas connections and drug approvals.
Defence Optics, Gas and Generic Drug Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Paras Defence and Space Technologies | 1,265.5 | 10,193 | 106.3 | 48.1 | 12.1 | 0.04 |
| Indraprastha Gas | 136.84 | 19,943 | 14.7 | 14.3 | 13.5 | 0.01 |
| Alembic Pharmaceuticals | 906.7 | 14,914 | 21.6 | 35.7 | 11.9 | 0.25 |
On valuation, Alembic Pharmaceuticals trades at a P/E below the industry P/E, while Paras Defence and Space Technologies and Indraprastha Gas trade above it, which reflects the growth the market already expects. Readers comparing defence optics, gas and generic drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in defence optics, gas and generic drug stocks can use the coming numbers to test whether growth is holding.
Why Do Defence Optics, Gas and Generic Drug Stocks Have a Strong Roadmap in India?
Defence optics, gas and generic drug stocks have a strong roadmap in India because rising defence electronics programmes, steady shift to cleaner fuels and wider generic drug demand keep widening the market for these companies.
- Defence optics. Armed forces add advanced equipment.
- Gas distribution. More vehicles and homes switch to gas.
- Generics. Regulated markets buy dependable supply.
Why Paras Defence and Space Technologies Features Among These Defence Optics, Gas and Generic Drug Stocks
Among the defence optics, gas and generic drug stocks on this list, Paras Defence and Space Technologies makes optics and electro-optics, defence electronics, heavy engineering products and space optics, and serves the defence, space and homeland security markets.
The company has a return on equity of 12.1%, a debt to equity ratio of 0.04 and a market capitalisation of Rs 10,193 crore. The stock trades at a P/E of 106.3, above the industry P/E of 48.1.
Revenue rose from Rs 186 crore in FY22 to Rs 493 crore in FY26, a compound annual growth rate of 27.6%. Net profit grew from Rs 27.1 crore in FY22 to Rs 89.5 crore in FY26, which works out to a compound annual growth rate of 34.8%. In the June 2026 quarter, revenue grew 35.9% year on year to Rs 130 crore, while net profit rose 45.3% to Rs 20.7 crore.
Roadmap: The company is among the few Indian private players in defence optics and has been adding capabilities in thermal imaging, anti-drone systems and space applications. Its products meet a steady need for indigenous sensors, optics and surveillance equipment.
What to watch: Track new order wins in optics and the progress of its newer product lines such as anti-drone and space-grade systems.
Why Indraprastha Gas Features Among These Defence Optics, Gas and Generic Drug Stocks
Among the defence, gas and pharma shares on this list, Indraprastha Gas distributes compressed natural gas to vehicles and piped natural gas to homes, businesses and industries in Delhi NCR and other licensed regions.
Revenue rose from Rs 7,887 crore in FY22 to Rs 16,541 crore in FY26, a compound annual growth rate of 20.3%. Net profit for FY26 was Rs 1,544 crore, a net margin of 9.3%.
In the June 2026 quarter, revenue grew 16.5% year on year to Rs 5,145 crore. The company has a return on equity of 13.5%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 19,943 crore. The stock trades at a P/E of 14.7, above the industry P/E of 14.3.
Roadmap: The company benefits from growing use of cleaner fuel in vehicles and homes and from new geographic areas it serves. A growing station network and household connections add to volumes.
What to watch: Track gas volumes, new station additions and input gas costs.
Why Alembic Pharmaceuticals Features Among These Defence Optics, Gas and Generic Drug Stocks
Among the three companies on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.
In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%.
Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7.
Roadmap: The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.
What to watch: Follow new approvals in the United States, the pace of complex generic launches and domestic growth.
Paras Defence and Space Technologies vs Indraprastha Gas vs Alembic Pharmaceuticals on Key Financials
The table below sets the three defence optics, gas and generic drug stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Paras Defence and Space Technologies | 186 | 493 | 27.6% | 89.5 | 18.2% |
| Indraprastha Gas | 7,887 | 16,541 | 20.3% | 1,544 | 9.3% |
| Alembic Pharmaceuticals | 5,356 | 7,399 | 8.4% | 671 | 9.1% |
Indraprastha Gas posts the highest return on equity in this group at 13.5%. Indraprastha Gas has the largest FY26 revenue at Rs 16,541 crore, and Paras Defence and Space Technologies shows the fastest revenue growth with a 27.6% compound annual rate. A useful habit with defence optics, gas and generic drug stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several night vision, vehicle gas and tablet stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Paras Defence and Space Technologies | 95.6 | 130 | 35.9% |
| Indraprastha Gas | 4,416 | 5,145 | 16.5% |
| Alembic Pharmaceuticals | 1,717 | 2,165 | 26.1% |
Key Risks to Check Before Investing in Defence Optics, Gas and Generic Drug Stocks
Every theme carries risks that deserve a check before any decision. For these defence optics, gas and generic drug stocks, the main points are: Long-term defence, gas and pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Order timing. Defence and space orders can shift between periods.
- Gas prices and rules. Gas costs and regulated tariffs can influence earnings.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter defence optics, gas and generic drug stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Defence Optics, Gas and Generic Drug Stocks
Defence optics, gas and generic drug stocks suit investors who prefer to study business strength before price moves. Paras Defence and Space Technologies, Indraprastha Gas and Alembic Pharmaceuticals each have a clear plan to grow. Based on the 4 November 2026 close, Paras Defence and Space Technologies trades at Rs 1,265.5, Indraprastha Gas at Rs 136.84 and Alembic Pharmaceuticals at Rs 906.7. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these defence optics, gas and generic drug stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track defence optics, gas and generic drug stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are defence optics, gas and generic drug stocks?
Ans. Defence optics, gas and generic drug stocks are listed companies that make optics and defence electronics, distribute compressed natural gas to vehicles and piped gas to homes, and sell generic formulations in India and abroad. Their earnings depend on defence orders, gas connections and drug approvals. This list looks at three of them, Paras Defence and Space Technologies, Indraprastha Gas and Alembic Pharmaceuticals, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.
Which defence optics, gas and generic drug stocks are covered in this list?
Ans. This list covers Paras Defence and Space Technologies, Indraprastha Gas and Alembic Pharmaceuticals. Based on the 4 November 2026 close, Paras Defence and Space Technologies traded at Rs 1,265.5, Indraprastha Gas at Rs 136.84 and Alembic Pharmaceuticals at Rs 906.7. Their return on equity ranges from 11.9% to 13.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 27.6%.
Why do defence optics, gas and generic drug stocks have a strong future roadmap in India?
Ans. Defence optics, gas and generic drug stocks have a strong roadmap in India because rising defence electronics programmes, steady shift to cleaner fuels and wider generic drug demand keep widening the market for these companies. The main drivers are as follows. Defence optics. Armed forces add advanced equipment. Gas distribution. More vehicles and homes switch to gas. Generics. Regulated markets buy dependable supply. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Paras Defence and Space Technologies performed financially?
Ans. Revenue rose from Rs 186 crore in FY22 to Rs 493 crore in FY26, a compound annual growth rate of 27.6%. Net profit grew from Rs 27.1 crore in FY22 to Rs 89.5 crore in FY26, which works out to a compound annual growth rate of 34.8%. In the June 2026 quarter, revenue grew 35.9% year on year to Rs 130 crore, while net profit rose 45.3% to Rs 20.7 crore. The company has a return on equity of 12.1%, a debt to equity ratio of 0.04 and a market capitalisation of Rs 10,193 crore. The stock trades at a P/E of 106.3, above the industry P/E of 48.1. Looking ahead, the company is among the few Indian private players in defence optics and has been adding capabilities in thermal imaging, anti-drone systems and space applications. Its products meet a steady need for indigenous sensors, optics and surveillance equipment.
How has Indraprastha Gas performed financially?
Ans. Revenue rose from Rs 7,887 crore in FY22 to Rs 16,541 crore in FY26, a compound annual growth rate of 20.3%. Net profit for FY26 was Rs 1,544 crore, a net margin of 9.3%. In the June 2026 quarter, revenue grew 16.5% year on year to Rs 5,145 crore. The company has a return on equity of 13.5%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 19,943 crore. The stock trades at a P/E of 14.7, above the industry P/E of 14.3. Looking ahead, the company benefits from growing use of cleaner fuel in vehicles and homes and from new geographic areas it serves. A growing station network and household connections add to volumes.
How has Alembic Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.
What risks should investors check before buying defence optics, gas and generic drug stocks?
Ans. Investors should check a few risks before buying defence optics, gas and generic drug stocks. Order timing. Defence and space orders can shift between periods. Gas prices and rules. Gas costs and regulated tariffs can influence earnings. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of defence optics, gas and generic drug stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
